Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease
- Sponsor
- Novartis Pharmaceuticals
- Study ID
- NCT02980263
- Phase
- PHASE2
- Status
- Withdrawn
Conditions
- Kawasaki Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 28 Days - 10 Years
- Healthy Volunteers
- Not accepted
Interventions
- Canakinumab — DRUG
Study Details
The purpose of this trial is to evaluate whether, in Intravenous Immunoglobulin-naïve or refractory patients diagnosed with active Kawasaki disease, administration of canakinumab controls fever and acute phase reactants.
Key Dates
- Start date
- Nov 15, 2016
- Status verified
- Feb 2017
- Primary completion
- Nov 30, 2017
- Completion
- Nov 30, 2017
Study Design
- Enrollment
- 0 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Kawasaki patients
Primary Outcome Measure
resolution of fever [ Time Frame: Day 3/4 ]
Related Studies
- Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at SanfordRecruiting · Sanford Health · Sioux Falls, South Dakota
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)Recruiting · Duke University · Phoenix, Arizona
- Kawasaki MATCH TrialRecruiting · University of California, San Diego · San Diego, California